Gilead Sciences, Inc. (GILD): Gilead Sciences’ CEO Discusses Q3 2013 Results …
Seeking Alpha
This application was supported by data from Study-10109, a single arm open label Phase 2 study of 125 patients who were refractory to both rituximab and alkylating agent chemotherapy. In this study Idelalisib achieved an overall response rate of 54 …
Gilead Sciences Announces Third Quarter 2013 Financial ResultsBusiness Wire (press release)

all 15 news articles »

Repeat Rituximab Courses Sustain Clinical Efficacy in Patients with RA
Monthly Prescribing Reference
SAN DIEGO, CA—A sustained improvement of clinical response was seen after each retreatment course with rituximab in patients with rheumatoid arthritis (RA), with respect to Treat to Target principles and EULAR/ACR recommendations, presented Catalin …

The Non-Hodgkin’s Lymphoma Drug Market Will Nearly Double to More Than …
The Providence Journal
The Pharmacor advisory service entitled Non-Hodgkin’s Lymphoma finds that sales of rituximab dominate the current market, and will continue to do so through 2022, regardless of biosimilar rituximab entry. Teva Pharmaceutical Industries’ …

and more »

The Non-Hodgkin’s Lymphoma Drug Market Will Nearly Double to More Than …
Sacramento Bee
The Pharmacor advisory service entitled Non-Hodgkin’s Lymphoma finds that sales of rituximab dominate the current market, and will continue to do so through 2022, regardless of biosimilar rituximab entry. Teva Pharmaceutical Industries’ …

and more »

Rituximab drug may be safe, effective for immunoglobulin G4-related disease …
News-Medical.net
Rituximab (Rituxan®) — a drug commonly used rheumatoid arthritis, granulomatosis with polyangiitis (formerly Wegener’s), and certain types of cancers — may be a safe and effective treatment for immunoglobulin G4-related disease (commonly called …

Common Rheumatoid Arthritis Treatment May Be Effective in Treating …
Science Daily (press release)
Oct. 27, 2013 — Rituximab (Rituxan®) — a drug commonly used rheumatoid arthritis, granulomatosis with polyangiitis (formerly Wegener’s), and certain types of cancers — may be a safe and effective treatment for immunoglobulin G4-related disease …

and more »

Common Rheumatoid Arthritis Treatment May Be Effective in Treating …
Newswise (press release)
Newswise — SAN DIEGO – Rituximab (Rituxan®) — a drug commonly used rheumatoid arthritis, granulomatosis with polyangiitis (formerly Wegener’s), and certain types of cancers — may be a safe and effective treatment for immunoglobulin G4-related …

Epratuzumab’s Mechanism of Action Featured in Blood, Official Journal of The …
HispanicBusiness.com
Accompanying the article was an invited commentary by Dr. Ronald P. Taylor of the University of Virginia School of Medicine , who is a pioneer on studies of trogocytosis involving anti-B-cell antibodies, such as rituximab. In the article by Rossi and …

and more »

Epratuzumab’s Mechanism of Action Featured in Blood, Official Journal of The …
MarketWatch
Accompanying the article was an invited commentary by Dr. Ronald P. Taylor of the University of Virginia School of Medicine, who is a pioneer on studies of trogocytosis involving anti-B-cell antibodies, such as rituximab. In the article by Rossi and …

and more »